







BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Name of the regimen and cancer drugs

- Bendamustine (BEN-duh-MUS-teen): Bendeka, Treanda
- Polatuzumab Vedotin-piiq (POH-lah-TOO-zoo-mab veh-DOH-tin): Polivy
- Rituximab (rih-TUK-sih-mab): Rituxan™, Ruxience™, Truxima™

Common uses

This regimen is most commonly used for Diffuse Large B-Cell Lymphoma but may be used for other diagnoses.

Treatment schedule

Your treatment will be given into your vein through an intravenous (IV) line. This may be into a short, flexible temporary catheter in your arm, or through a central venous catheter. A central venous catheter, or central line is a long, flexible IV tube that empties into a very large vein next to the heart. Talk with your care team to see which will be best for you and your treatment.

Each bendamustine/polatuzumab vedotin + rituximab treatment is repeated every 21 days. This is known as one cycle. Your treatment may be given for a set number of cycles, or it will keep going until the drug, or drugs, stop working or you have side effects which stop you from continuing treatment.

- □ Bendamustine IV on days 1-2
- Polatuzumab vedotin IV on day 1
- □ Rituximab IV given on Day 1

Drug	Cycle 1	Day 1	2	3	4	5	6	7	8	 21	Cycle 2 Day 1
Bendamustine											
Polatuz	zumab vedotin										
Rituximab											









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Other medications

Other medications may be ordered for you to prevent or treat certain side effects. These include:

	Instructions:
Growth Factors	Growth factors, like filgrastim, pegfilgrastim, and others, are medications used to treat neutropenia and prevent infections. Neutropenia is a condition where there are lower-than-normal white blood cells caused by some type of chemotherapy. Growth factors help the bone marrow to make more white blood cells.
Medications to prevent allergic reactions	You will receive medications to prevent infusion related reactions prior to starting your cancer treatment.
Anti-nausea medications	You will receive medications to prevent nausea just before your cancer treatment. You may also get prescriptions to take at home, as below:
Medications to prevent side effects	You will receive your medications to prevent side effects just before your cancer treatment. You may get prescriptions for other medications to take at home, as below:
Infection prevention	There is a risk of serious infections during treatment. You may receive medications to prevent infection in the hospital, and may also get prescriptions for medications to take at home for infection prevention, as below:









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Possible drug interactions

- Bendamustine/polatuzumab vedotin + rituximab may interact with other drugs you are taking. Please inform your care providers of all prescription medicine, over-the-counter medications, vitamins, and herbal products that you take.
- □ Talk with your care provider or pharmacist before taking new medications, supplements, or receiving any vaccines.
- ☐ Grapefruit or grapefruit juice may interact with bendamustine/polatuzumab vedotin-piiq + rituximab. Avoid eating or drinking these during your treatment

Common Side Effects

Common side effects that have been known to happen in patients receiving bendamustine/polatuzumab vedotin + rituximab are listed in the left side of this table. In some instances, the side effects may be reported less often but are still important to discuss. This table does not list all the known side effects for this therapy, only the ones that are experienced most often. Not every patient experiences every known side effect of a drug; even if you are taking the same drug as another patient, you may experience different side effects. Options to help manage any side effects that do occur are included on the right side of this table. These should be discussed with your care provider. If you experience any side effect you cannot manage or that is not listed here, contact your care provider.

Possible Side Effect	Management
Decreased white blood cells (WBCs) and increased risk for infection	Your WBCs should be monitored by a simple blood test. When your WBCs are low, you are at a greater risk of having an infection. Take the following precautions to protect yourself from infection. • Wash your hands often, especially before eating and after using the bathroom. • Avoid crowds and people with fevers, flu, or other infection. • Bathe often for good personal hygiene. Contact your care team if you experience any signs or symptoms of an infection such as: • Fever (temperature more than 100.4°F or 38°C) • Chills • Sore throat • Burning when peeing • Tiredness that is worse than normal • A sore that becomes red, is draining, or does not heal. Check with your care team before taking any medicine for a fever or chills.
	Continued on the next page









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Possible Side Effect	Management
Decreased platelet count and increased risk of bleeding	Your platelets should be monitored by a simple blood test. When they are low, you may bruise or bleed more easily than usual. Use caution to avoid bruises, cuts, or burns. Blow your nose gently and do not pick your nose Brush your teeth gently with a soft toothbrush and maintain good oral hygiene When shaving use an electric razor instead of razor blades Use a nail file instead of a nail clippers Call your care team if you have bleeding that won't stop. Examples include: A bloody nose that bleeds for more than 5 minutes despite pressure A cut that continues to ooze despite pressure Gums that bleed a lot when you floss or brush Seek medical help right away if you have any severe headaches, blood in your urine or stool, coughing up blood, or bleeding that you cannot stop or lasts a long time. You may need to take a break or "hold" your medication for medical or dental procedures. Talk to your care team or dentist before any scheduled procedures.
Decreased hemoglobin, part of the red blood cells that carry iron and oxygen	Your hemoglobin should be checked by a simple blood test. When your hemoglobin is low, you may notice that you get tired or fatigued more easily. Try to get 7 to 8 hours of sleep per night Avoid operating heavy machinery if you feel too tired Find a balance between "work" and "rest" Stay as active as possible, but know that it is okay to rest as needed, too You might notice that you are more pale than usual Let your care team know right away if you have: Shortness of breath Dizziness Fast or abnormal heartbeat
	Continued on the next page









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Possible Side Effect	Management
Infusion Reaction	During your treatment, let the nurse know right away if any of these symptoms happen: Chills or shaking Dizziness Fever Itchiness or rash Flushing Difficulty breathing Wheezing Throat irritation Cough Congestion Sudden back pain Feeling faint
Numbness or tingling in hands and feet	Report changes in your sense of touch, such as a burning feeling, pain on the skin or weakness. Notify your care team as soon as these symptoms develop. Early intervention can limit and resolve these symptoms, but if not addressed these symptoms can become permanent.
Diarrhea (loose and/ or urgent bowel movements)	Monitor how many bowel movements you have each day. Drink 8-10 (8-ounce) glasses of water or fluid each day unless your care team has asked you to limit your fluid intake. Eat small, frequent meals throughout the day rather than a few large meals. Eat bland, low-fiber foods (such as bananas, applesauce, potatoes, chicken, rice, and toast). Avoid high fiber foods, such as raw vegetables and fruits and whole grains. Avoid foods that cause gas, such as broccoli and beans. Avoid foods with lactose, such as yogurt and milk. Avoid spicy, fried, and greasy foods. Contact your care team if: The number of bowel movements you have in a day increases by 4 or more You feel dizzy or lightheaded Talk with your care team if you believe you have diarrhea. They may recommend an over-the-counter medication or prescribe something to help keep it under control.
	Continued on the next page









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Possible Side Effect	Management
Fatigue	 You may be more tired than usual or have less energy. Stay as active as possible, but know it is okay to rest as needed. Try to do some type of moderate activity every day. Conserve your energy. Plan your activities and do them at a time of day when you feel a bit more energetic. Follow a healthy diet and stay hydrated. Accept help from family and friends Find healthy ways to manage stress, such as meditation, journaling, yoga, and guided imagery Develop good sleeping habits, limit napping during the day to help you sleep better at night. Avoid operating heavy machinery if you feel too tired. Contact your care team if you experience extreme fatigue that prevents you from doing your normal daily activities.
Fever	You may feel hot, cold and shivery, achy or dizzy. This usually starts during the first month of therapy but could happen at any time. • Call your doctor immediately if you have a fever 100.4° F Ask your doctor if you can take medicine to help with the fever
Nausea or vomiting	 Take all medications as prescribed to help prevent and lessen symptoms of nausea and vomiting Eat and drink slowly Drink 8-10 (8-ounce) glasses of water and/or fluid (soup or broth) each day unless your care team has instructed you to limit your fluid intake Eat small, frequent meals throughout the day rather than a few large meals Eat bland foods; avoid spicy, fried, and greasy foods Avoid intense exercise immediately after eating Don't lay down right away after eating Wear loose fitting clothing for comfort Avoid strong odors. Consider getting fresh air and try deep breathing. Let your care team know if you have nausea or vomiting. Your care team may prescribe medication to help with the symptoms.
Reactivation of Hepatitis B Virus (HBV)	 This medication can cause hepatitis B virus (HBV) reactivation in patients previously infected with HBV. You may be tested for HBV prior to beginning treatment with this medication. Be sure your healthcare provider is aware of any previous HBV diagnosis and treatment, if known. Patients with past HBV infection may need preventative antiviral medication while receiving and for months after completing this medication. Additional routine monitoring of HBV levels may be needed in patients who were previously infected with HBV.









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Rare but serious side effects

	(INSTITUTIONAL CONTACT INFO)
If y	ou experience ANY new, worsening, or uncontrolled side effects, call your care team immediately.
	Live vaccinations: Talk to your care team before getting any vaccines while taking rituximab.
	Bendamustine may result in toxicity to the skin. Please notify your healthcare provider if you have any signs of acne-like rashes (skin that is scaly, dry, cracking, or inflamed), skin infections, and or eye infections/loss of vision.
	Bendamustine/polatuzumab vedotin + rituximab may cause a condition called tumor lysis syndrome when starting treatment. This results from the rapid destruction of cancer cells in the body during the initial cycles of treatment. Your care team may do blood tests to check for this.
	Bendamustine/polatuzumab vedotin + rituximab can rarely cause an infusion reaction. During your treatment, let the nurse know right away if any of these symptoms happen: chills or shaking, dizziness, fever, itchiness or rash, flushing, difficulty breathing, wheezing, sudden back pain, or feeling faint.
	Bendamustine/polatuzumab vedotin + rituximab increases your risk of severe and life-threatening infections. Contact your doctor If you are experiencing any signs or symptoms of an infection including fever and chills, cough, shortness of breath, or fatigue, or if you have any suspicion that you are infected.
	Bendamustine/polatuzumab vedotin + rituximab may be harmful to your liver. Speak to your care team to know when you need to have blood tests done to monitor your liver function. If you get this side effect, your doctor may change your dose or stop treatment for some time.

Handling body fluids and waste

Some of the drugs you receive may be present in urine, stool, sweat, or vomit for many days after treatment. Many cancer drugs are toxic, your bodily waste may also be toxic and can be dangerous to come into contact with. Once you have started bendamustine/polatuzumab vedotin + rituximab, follow the instructions below for at least two days after your treatment. This is to keep you, your loved ones, and the environment as safe as possible.

	Pregnant women	should avoid	touching any	thing that m	nay be soiled	with body fluids	from the patient.
--	----------------	--------------	--------------	--------------	---------------	------------------	-------------------

- □ Toilet and septic systems
 - You may use the same toilet, septic tank, and/or sewer that you usually use. Close the lid and flush to ensure all waste has been discarded. If you have a low-flow toilet, close the lid and flush twice. If the toilet or toilet seat is soiled with urine, stool, or vomit, clean the surface after every use before other people use the toilet.

f the toilet or toilet seat becomes soiled with urine, stool, or vomit, clean the surface after every use before other people use
he toliet.

				_	_	_	-		_	_			-
_	11/100h	hands with		1 +	otto.		+6 ~ +4	-:1-+	t~~~+	1000+	ററ		4~
	Wacn	Hanne willin	enan and	1 1/1/21/41	all ar	HEHM	1114 11	11141	IM at	14461	<i>_</i>	CACOL	U.C.

- ☐ If you need a bedpan, be sure your caregiver knows to wear gloves to assist with cleanup and to wash the bedpan with soap and water every day.
- ☐ If you do not have good control of bladder or bowels, use a disposable pad with a plastic back, a diaper, or a sheet to absorb body waste.









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Handling body fluids and waste (continued)

Wash any skin that has been exposed to body waste with soap and water.
Linens or clothing that are soiled with body fluids or body waste should be washed separately from other linens and clothing. If you do not have a washer, place the soiled linens in a plastic bag until they can be washed.
Wash hands with soap and water after touching linens or clothing that may be soiled with body fluids.

Intimacy, sexual activity, contraception, and fertility

This treatment may cause changes that can affect intimacy and sexuality, including desire and body image. Maintaining physical closeness and/or intimacy with loved ones can be continued during treatment. Holding hands, hugging, and kissing can be done safely. It is recommended that you talk to your care team about any restrictions or questions you may have.

Some treatments can influence the ability to have children, also known as fertility. If you're interested in preserving fertility, talk to your care team before treatment. Ask your healthcare provider to determine when it is safe to become pregnant after your treatment. Patients of reproductive ability should not become pregnant or get their partners pregnant while receiving bendamustine/polatuzumab vedotin + rituximab. Some of the drugs you receive may be present in semen and vaginal secretion for many days after treatment. You should use barrier devices, such as condoms, during sexual activity to limit exposure to body fluids.

Talk to your care team about birth control. Not all options may be right for your treatment or cancer. Effective contraception
could include one or more of the following: barrier methods (e.g. condoms), hormone methods (e.g. birth control pills), or
surgery.

	Tell vou	care.	team if v	vou become	nregnant o	r nlan to	hreastfeed
_	I GII y G G I	Gaic	toaiii ii '	vou becenile	Di Gullalli U	n biaii tu	DIGASTICGA









BENDAMUSTINE/POLATUZUMAB VEDOTIN + RITUXIMAB

Additional resources

Prescribing information:

Bendamustine: https://www.bendekahcp.com/?utm_source=google&utm_medium=cpc&utm_campaign=USA_GO_SEM_B_EX_Bendeka-HCP-Generic-NA-All-All-NA-BA-All&utm_term=bendamustine&utm_content=Bendamustine+Info&gclid=Cj0KCQjw0JiXBhCFARIsAOSAKqB6cdSf7ktkA-4A8XhzaYPCSizdIBKVQDchdtdCX905yWOqJTx4DikaAs28EALw_wcB&gclsrc=aw.ds

Polatuzumab vedotin-piiq: https://www.polivy.com/

Rituximab: https://www.rituxan.com/

Additional instructions

Updated – May 3, 2023

Important notice: The Association of Community Cancer Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), National Community Oncology Dispensing Association, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated in gathering information for and developing this patient education guide. This guide represents a brief summary of the therapy derived from information provided by the drug manufacturer and other resources. This guide does not cover all existing information related to the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this therapy and should not substitute for the advice of a qualified healthcare professional. Provision of this guide is for informational purposes only and does not constitute or imply endorsement, recommendation, or favoring of this therapy by ACCC, HOPA, NCODA, or ONS, who assume no liability for and cannot ensure the accuracy of the information presented. The collaborators are not making any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual receiving therapy. All decisions related to receiving this therapy should be made with the guidance and under the direction of a qualified healthcare professional.

Permission: Intravenous Cancer Treatment Education (IVE) sheets are provided as a free educational resource for patients with cancer in need of concise, easy-to-understand information about intravenous cancer therapy. Healthcare providers are permitted to copy and distribute the sheets to patients as well as direct patients to the OCE website for information. However, commercial reproduction or reuse, as well as rebranding or reposting of any type, are strictly prohibited without permission of the copyright holder. Please email permission requests and licensing inquiries to Contact@NCODA.org.

Copyright © 2023 by NCODA. All rights reserved.